Chemosensitivity Testing in Oncology

Over the past 50 years many in vitro and in vivo drug response assay systems have been developed to determine the potential - tivity of chemotherapy agents. The idea was to eliminate ineffective agents and unnecessary toxic treatment while selecting drugs active in vitro or in the mouse model that might increase the probability of response in the patient. None of these test models, however, achieved routine clinical application in the past. This might be at least in part - lated to large discrepancies that were described between the s- cess rate of the assay systems and the clinical benefit in cancer - tients. The heterogeneity of chemosensitivity that exists between different tumors as well as between individual tumor lesions may be one explanation for these findings. Furthermore, different assay end points such as proliferation, metabolism, and vitality were - veloped to evaluate the effects of cytostatic drugs on tumor cells, and these might be related to the differing results. However, knowledge about procedures for assay-assisted treatment selection has increased rapidly within the past few years, and several studies suggest that test-directed chemotherapy selection now may - prove response rates and survival in various types of tumors. The International Society for Chemosensitivity Testing in - cology (ISCO) was founded to promote, coordinate, and improve clinical and laboratory research in the field of predictive drug te- ing in human tumor cells.

Klappentext

The last decade has seen a renaissance of the concept of individualized chemotherapy in oncology, markedly stimulated by the development of new in vitro chemosensitivity assays. The clinical utility of drug response assays has been evaluated in clinical trials and the results suggest that assay-assisted therapy selection may improve survival as well as economic outcomes. This volume comprises the proceedings of the first Symposium of the International Society for Chemosensitivity Testing in Oncology, ISCO-1, held in Homburg/Saar, Germany, in September 2001. The topics include: new in vitro drug-testing methods, tumor chemosensitivity assays, and the clinical relevance of assay-directed therapy.

Inhalt
1 In Vitro Drug Testing Methods: Recent Developments.- Luminescence Applications for Chemotherapeutic Drug Development.- The Use of the MTT Assay to Study Drug Resistance in Fresh Tumour Samples.- Chemosensitivity Testing of Human Tumors Using Si-sensor Chips.- Multiparametric Sensor Chips for Chemosensitivity Testing of Sensitive and Resistant Tumor Cells.- Development of New In Vitro Chemosensitivity Test Using Collagen Gel Droplet Embedded Culture and Image Analysis for Clinical Usefulness.- In Vitro Chemosensitivity Testing of Hematological Cancer Patients: Detection of Ornithine Decarboxylase.- 2 Tumor Chemosensitivity Assays: Evaluation of In Vitro Results.- The Chemosensitivity Profile of Retinoblastoma.- Chemosensitivity Testing in Malignant Melanoma.- Human Melanoma: Drug Resistance.- Cisplatin, Doxorubicin and Paclitaxel Induce mdr1 Gene Transcription in Ovarian Cancer Cell Lines.- 3 Clinical Relevance of Tumor-Directed Therapy.- Chemosensitivity Testing as an Aid to Anti-Cancer Drug and Regimen Development.- Assay-Assisted Treatment Selection for Women with Breast or Ovarian Cancer.- Chemosensitivity Testing in Gynecologic Oncology Dream or Reality?.- Treosulfan in the Treatment of Metastatic Melanoma: From Chemosensitivity Testing to Clinical Trials.- Chemosensitivity Testing and Test-Directed Chemotherapy in Human Pancreatic Cancer.- Clinical Significance of Cellular Drug Resistance in Childhood Leukemia.- ATP Chemosensitivity Testing in Ovarian and Breast Cancer: Early Clinical Trials.- Chemosensitivity Testing Present and Future in Japan.